Dupixent

Mar 25, 2022

Dupixent (dupilumab) is a non-immunosuppressive fully human monoclonal antibody that inhibits the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. According to data from Dupixent clinical trials, IL-4 and IL-13 are key drivers of type 2 inflammation, which is a major contributor to Atopic...

Jun 27, 2019

Sanifit raises USD 80.9 M to advance Calciphylaxis Pipeline Sanifit, a clinical-stage biopharmaceutical company, has raised USD 80.9 million ( €72.2 million ) in total private fundraising. The financing mainly consisted led by Spain’s Caixa Capital Risc, along with many new investors, including Columbus Venture ...